Difference between 4-PrO-MET vs. Psilocybin and LSD

For millennia, humans have sought ways to understand the mind and heal its ailments. In ancient cultures, certain mushrooms were revered for their profound, consciousness-altering properties. Today, modern science is rediscovering the therapeutic potential of psilocybin, the active ingredient in these "magic mushrooms." However, to unlock its full potential for mental health, we must move beyond the mushroom itself and enter the world of precision medicine.

This is the story of a molecule's journey—and its analogous relatives like 4-PrO-MET—from sacred ritual to the laboratory, and how their synthetic, precisely dosed forms can not only revolutionize the treatment of our mental suffering but also profoundly expand our experiential world. But what exactly is the difference between 4-PrO-MET, LSD, and psilocybin? This article aims to bring some clarity to this question.

While indigenous cultures in Mesoamerica used psilocybin-containing mushrooms for centuries, their existence was largely unknown in the Western world until the mid-20th century. The pivotal moment came in 1957, when amateur mycologist and J.P. Morgan vice president, R. Gordon Wasson, published a groundbreaking photo essay titled "Seeking the Magic Mushroom" in LIFE magazine. In it, he detailed his experiences during a mushroom ceremony with traditional Mazatec healer María Sabina in Oaxaca, Mexico. The article caused a stir, introducing a broad audience to the concept of psychedelics and piquing the curiosity of an entire generation.

This newfound awareness quickly attracted the attention of the scientific community. A year later, in 1958, Swiss chemist Albert Hofmann, who had already discovered lysergic acid diethylamide (LSD) two decades earlier, succeeded in isolating psilocybin and its active metabolite psilocin from mushroom samples sent to him by Wasson. Hofmann worked at Sandoz Laboratories, where he not only identified these compounds but also synthesized them, making them available for psychiatric research. In the early 1960s, promising studies explored psilocybin's potential to treat alcoholism, anxiety, and depression. However, as psychedelics left the labs and, together with Timothy Leary, became symbols of the 1960s counterculture, a moral panic ensued.

By 1970, psilocybin and LSD were classified as Schedule I drugs under the U.S. Controlled Substances Act, effectively halting all legitimate research for decades. The use of these substances in medications, medicine, or psychological research was also put on hold.

Despite the natural appeal of dried mushrooms for therapeutic purposes, there is a fundamental scientific problem: unstable psilocybin concentration. This significantly complicates controlled experimental applications.

The psilocybin concentration in mushrooms varies widely. It can differ not only between species, but also between different mushrooms of the same species, and even between the cap and stem of a single mushroom. Studies have shown that the psilocybin content of the widespread species Psilocybe cubensis can fluctuate by a factor of ten or more.

These fluctuations make accurate dosing almost impossible. For example, a 2-gram dose of dried mushrooms can contain a mild 10 mg or a strong 40 mg of psilocybin. In a therapeutic context, where precision is paramount for both safety and efficacy, this presents an unacceptable risk.

Furthermore, besides psilocybin, mushrooms contain a mixture of other alkaloids such as baeocystin and norbaeocystin. While these compounds are less psychoactive, they are often associated with undesirable physical side effects, particularly nausea, body load, muscle weakness, and general discomfort. These physical impairments can disrupt the therapeutic process and distract patients from the valuable psychological work they are meant to undertake.

Albert Hofmann first synthesized psilocybin in 1958 at Sandoz Laboratories in Basel. The pure, crystalline form obtained was chemically identical to the natural active ingredient from mushrooms. Hofmann's synthesis also opened the door to a broader understanding of psychedelic tryptamines and made precise dosages possible.

Tryptamines are a class of organic compounds based on the amino acid tryptophan. They are found in plants, fungi, animals, and also in the human body. Many act as neurotransmitters or neuromodulators, such as serotonin and melatonin. Numerous psychedelic substances, including psilocybin, DMT, and 5-MeO-DMT, also belong to the tryptamine family. Their effects are exerted by binding to serotonin receptors, particularly the 5-HT2A receptor.

Psychedelics, a term from Greek for "mind- or soul-revealing," was coined in 1956 by British psychiatrist Humphry Osmond to establish a more positive term than "hallucinogen." Chemically, they resemble the neurotransmitter serotonin, which influences our mood, perception, and thoughts. Unlike alcohol, nicotine, cocaine, and opioids, psychedelics are not addictive and do not cause withdrawal symptoms. In normal doses, they cause no physical harm, and for substances like psilocybin, no lethal dose is known. Their effect is neither calming nor stimulating, but consciousness-altering, without interfering with the reward system.

The core structure of psilocybin can be modified by chemists to create new molecules, referred to as analogues or research chemicals. For example, there are legal analogues such as  4-PrO-MET (4-propoxy-N,N-dimethyltryptamine), which are very similar to psilocybin in their chemical structure and effects. Since their exact chemical formula is not always explicitly listed in legal regulations, these substances do not fall under controlled substance laws in many countries.

Psilocybin (known from "magic mushrooms") and  4-PrO-MET are "prodrugs." This means their effects only manifest after the body converts them into active substances. Psilocybin is converted into psilocin (C₁₂H₁₆N₂O), while 4-PrO-MET is converted into 4-HO-MET (C₁₃H₁₈N₂O).

The two active forms, psilocin and 4-HO-MET, are chemically very similar. You can imagine them as almost identical twins. The only difference is that one of 4-HO-MET's "arms" is one link longer than the corresponding arm of psilocin. The active substance 4-HO-MET has exactly one carbon atom and two hydrogen atoms more than psilocin. Both trigger altered sensory perceptions, new ways of thinking, and intense emotions.

While the nuances in the effects of 4-HO-MET and psilocin are subtle, they are often distinctly perceptible to users and significantly shape the respective experience. 4-HO-MET, a synthetic tryptamine, is frequently described as a substance that intensifies visual experience and creates a rather stimulating, sometimes even playful effect. This can manifest in vivid color perceptions, geometric patterns, or heightened detail recognition. Accompanying this, a certain euphoria and a feeling of lightness are often reported, which can lead to a more extroverted and social experience. The mental clarity tends to remain higher and less introspective than with other psychedelics.

In contrast, psilocin, the active metabolite of psilocybin found in "magic mushrooms," is known for its profound and emotionally immersive effects. Here, the focus is less on visual stimulation and more on internal processes. Users frequently report intense emotional breakthroughs, ranging from deep joy to melancholic or contemplative states. The effects can lead to intense introspection and a feeling of delving deep into one's own subconscious. This is often described as a spiritual or therapeutic experience, where old patterns can be broken and new perspectives gained. Physical stimulation is generally less than with 4-HO-MET or 4-PrO-MET, and the experience can be perceived as more grounding and inwardly directed.

In summary, 4-HO-MET is more valued for a visually rich and stimulating, potentially social experience, while psilocin enables a deeper, more emotional and introspective journey, often associated with personal insights and spiritual realizations.

Thanks to its purity and the absence of other alkaloids, 4-PrO-MET generally has better tolerability compared to natural magic mushrooms; according to user reports, nausea and an unpleasant body load occur less frequently.

Compared to LSD, 4-PrO-MET has a shorter duration of action and is less introspective, but more playful and often lighter.

The commonality of these three substances lies in their psychedelic effect, which serves many people as a tool for personal growth and also plays a significant role in research – especially for a deeper understanding of consciousness.